Carlo Castellani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carlo Castellani has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Baroukh M. Assael
Cystic Fibrosis Centre, Azienda Ospedaliera di Verona, Verona, Italy
2 shared publicationsLuigi Picci
2 shared publicationsPaolo Rizzotti
2 shared publicationsA. Brown
UK CF Trust Representative, United Kingdom
1 shared publicationA. Munck
Cystic Fibrosis Centre, Hospital Robert Debré, Paris, France
1 shared publication- Alan Robert Smyth
School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, Northern Ireland, United Kingdom
1 shared publication
Latest Publications
- 1 July 2011
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 66 (7) , 406-407
An Interactive Computer Program Can Effectively Educate Potential Users of Cystic Fibrosis Carrier Tests
A Consensus Statement (Genetic Testing for Cystic Fibrosis, NIH Consensus Statement, 1997) concluded that carrier testing for cystic fibrosis (CF) should be offered not only to adults who are at increased reproductive risk due to a positive family history of CF but also to their partners and to couples from the general population planning a pregnancy. Subsequently, several professional medical organizations issued similar recommendations for widespread genetic testing for CF. Education of any individual planning to undergo genetic testing on the nature of the disease, risk of genetic transmission, and the test itself is best achieved with a face-to-face genetic counseling (GC) session. However, GC is costly, time-consuming, and there are too few trained professionals to meet the demand for testing. With the continuing increase in the number of genetic tests available for clinical use, alternative educational and counseling methods are needed. Although health education materials such as booklets and videotapes are available, these are of limited value because the information provided is inadequate and they do not allow for interaction with the end user. In recent years, an interactive computer-based (IC) program has shown effectiveness for providing adequate information to individuals who were undergoing testing for a genetic disease or were scheduled for a medical or surgical procedure. This interventional randomized clinical trial compared the efficacy of the IC program and a traditional GC session to educate potential users of the CF carrier test about the disease and benefits and limitations of carrier testing. Individuals undergoing an assisted reproduction protocol were randomly assigned to participate either in an IC-assisted session (n = 22) or a GC session (n = 22). A multiple-choice questionnaire was administered both before and after the educational intervention to assess improvements among the participants regarding knowledge and understanding of several issues related to CF carrier testing. The study was conducted for a period of 1 year, starting in 2008. The precounseling knowledge level (baseline) was similar in both groups (IC group: 45% vs. GC group: 47%). After the counseling sessions, there was a statistically significant improvement from baseline in the proportion of correct answers in each group (P < 0.0001 for both), but no difference was found between the groups in the number of correct answers (85% in the IC group and 84% in the GC group). None of the participants in either group changed their intention to undergo testing. These findings show that interactive education by computer is as effective an educational tool for potential users of the CF carrier test as individual face-to-face counseling.
- 1 July 2011
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 66 (7) , 406-407
An Interactive Computer Program Can Effectively Educate Potential Users of Cystic Fibrosis Carrier Tests
A Consensus Statement (Genetic Testing for Cystic Fibrosis, NIH Consensus Statement, 1997) concluded that carrier testing for cystic fibrosis (CF) should be offered not only to adults who are at increased reproductive risk due to a positive family history of CF but also to their partners and to couples from the general population planning a pregnancy. Subsequently, several professional medical organizations issued similar recommendations for widespread genetic testing for CF. Education of any individual planning to undergo genetic testing on the nature of the disease, risk of genetic transmission, and the test itself is best achieved with a face-to-face genetic counseling (GC) session. However, GC is costly, time-consuming, and there are too few trained professionals to meet the demand for testing. With the continuing increase in the number of genetic tests available for clinical use, alternative educational and counseling methods are needed. Although health education materials such as booklets and videotapes are available, these are of limited value because the information provided is inadequate and they do not allow for interaction with the end user. In recent years, an interactive computer-based (IC) program has shown effectiveness for providing adequate information to individuals who were undergoing testing for a genetic disease or were scheduled for a medical or surgical procedure. This interventional randomized clinical trial compared the efficacy of the IC program and a traditional GC session to educate potential users of the CF carrier test about the disease and benefits and limitations of carrier testing. Individuals undergoing an assisted reproduction protocol were randomly assigned to participate either in an IC-assisted session (n = 22) or a GC session (n = 22). A multiple-choice questionnaire was administered both before and after the educational intervention to assess improvements among the participants regarding knowledge and understanding of several issues related to CF carrier testing. The study was conducted for a period of 1 year, starting in 2008. The precounseling knowledge level (baseline) was similar in both groups (IC group: 45% vs. GC group: 47%). After the counseling sessions, there was a statistically significant improvement from baseline in the proportion of correct answers in each group (P < 0.0001 for both), but no difference was found between the groups in the number of correct answers (85% in the IC group and 84% in the GC group). None of the participants in either group changed their intention to undergo testing. These findings show that interactive education by computer is as effective an educational tool for potential users of the CF carrier test as individual face-to-face counseling.
- 11 April 2011
- Published by Springer Nature
- Vol. 742, 355-372
Evaluation of the Disease Liability of CFTR Variants
Over 1600 novel sequence variants in the CFTR gene have been reported to the CF Mutation Database (http://www.genet.sickkids.on.ca/cftr/Home.html). While about 25 mutations are well characterized by clinical studies and functional assays, the disease liability of most of the remaining mutations is either unclear or unknown. This gap in knowledge has implications for diagnosis, therapy selection, and counseling for patients and families carrying an uncharacterized CFTR mutation. This chapter will describe a critical approach to assessing the disease implications of CFTR mutations utilizing clinical data, literature review, functional testing, and bioinformatic in silico methods.
- 11 April 2011
- Published by Springer Nature
- Vol. 742, 355-372
Evaluation of the Disease Liability of CFTR Variants
Over 1600 novel sequence variants in the CFTR gene have been reported to the CF Mutation Database (http://www.genet.sickkids.on.ca/cftr/Home.html). While about 25 mutations are well characterized by clinical studies and functional assays, the disease liability of most of the remaining mutations is either unclear or unknown. This gap in knowledge has implications for diagnosis, therapy selection, and counseling for patients and families carrying an uncharacterized CFTR mutation. This chapter will describe a critical approach to assessing the disease implications of CFTR mutations utilizing clinical data, literature review, functional testing, and bioinformatic in silico methods.
- Open Access
- 16 December 2009
- Published by American Medical Association (AMA) in JAMA
- Vol. 302 (23) , 2573-2579
Association Between Carrier Screening and Incidence of Cystic Fibrosis
Quiz Ref ID Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CF transmembrane regulator (CFTR) gene (RefSeq NM_000492).1 In Europe, the median birth incidence of CF is 1 in 3500.2 Fluctuations in the number of annual CF births have been repeatedly reported,3-5 and some studies suggest a progressive decrease in CF birth incidence.3,6 However, these trends were recorded in populations diagnosed because of symptoms and are subject to ascertainment bias. The number of diagnoses may be incomplete for recent years, because patients may not yet be diagnosed or some patients could be lost before they are diagnosed. Incidence may be better appreciated when the analysis is performed on CF populations diagnosed through neonatal screening programs.
- 16 December 2009
- Published by American Medical Association (AMA) in JAMA
- Vol. 302 (23) , 2573-2579
Open AccessAssociation Between Carrier Screening and Incidence of Cystic Fibrosis
Quiz Ref ID Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CF transmembrane regulator (CFTR) gene (RefSeq NM_000492).1 In Europe, the median birth incidence of CF is 1 in 3500.2 Fluctuations in the number of annual CF births have been repeatedly reported,3-5 and some studies suggest a progressive decrease in CF birth incidence.3,6 However, these trends were recorded in populations diagnosed because of symptoms and are subject to ascertainment bias. The number of diagnoses may be incomplete for recent years, because patients may not yet be diagnosed or some patients could be lost before they are diagnosed. Incidence may be better appreciated when the analysis is performed on CF populations diagnosed through neonatal screening programs.
- 1 May 2009
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 8 (3) , 153-173
European best practice guidelines for cystic fibrosis neonatal screening
- 1 May 2009
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 8 (3) , 153-173
European best practice guidelines for cystic fibrosis neonatal screening
- Top Cited Papers
- 1 May 2008
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 7 (3) , 179-196
Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice
- 1 May 2008
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 7 (3) , 179-196
Top Cited PapersConsensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice
- 15 August 2007
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 143A (16) , 1936-1937
TG15 T5 allele in clinically discordant monozygotic twins with cystic fibrosis
- 15 August 2007
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 143A (16) , 1936-1937
TG15 T5 allele in clinically discordant monozygotic twins with cystic fibrosis
- 31 December 2006
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 5 (4) , 229-235
The genetic background of osteoporosis in cystic fibrosis: Association analysis with polymorphic markers in four candidate genes
- 31 December 2006
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 5 (4) , 229-235
The genetic background of osteoporosis in cystic fibrosis: Association analysis with polymorphic markers in four candidate genes